Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1290-1292

  Strumberg, D ^a   Erhard, J ^b   Harstrick, A ^a   Klaassen, U ^a   Muller C ^a   Eberhardt, W ^a   Wilke, H ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Hepatocellular carcinoma; Paclitaxel; Phase I

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0032127775     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00054-9     Document Type: Article

References (10)

1. 1. Flickinger JC, Carr BI, Lotze MT. Hepatobiliary cancers. Cancer of the liver. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia, Lippincott, 1997, 1087-1113.
2. 2. Arbuck SG, Blaylock BA. Dose and schedule issues. In McGuire WP, Rowinsky EK, eds. Paclitaxel in Cancer Treatment. New York, Marcel Dekker, 1995.
3. 3. Rowinsky EK, Donehower RC, Tucker RW. Microtubule changes and cytotoxicity in leukemic cells treated with taxol. Cancer Res 1988, 48, 4093-4100.
4. 4. Lopes NM, Adams EG, Pitts TW, et al Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cancer cell lines. Cancer Chemother Pharmacol 1993, 32, 235-242.
5. 5. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996, 32A(3), 547-549.
6. 6. Investigator's Handbook. A manual for participants in clinical trials of investigational agents. Cancer therapy evaluation program, division of cancer treatment. National Cancer Institute, Bethesda, Maryland (October 1993).
7. 7. Simon RM. Design and analysis of clinical trials. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 5th edition. Philadelphia, JB Lippincott, 1997, 513-534.
8. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984, 68, 487-491.
9. 9. Falkson G, Coetzer BJ, Terblance APS. Phase II mitoxantrone in patients with primary liver cancer. Cancer Treat Rep 1984, 68(10), 1311-1312.
10. 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989, 60, 928-933.